trending Market Intelligence /marketintelligence/en/news-insights/trending/njCYcYYt_dWHBMVyMWgjJw2 content esgSubNav
In This List

Endo's global R&D chief to leave as 2 join branded drug business

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Endo's global R&D chief to leave as 2 join branded drug business

Endo International PLC said two executives will leave the company following a reorganization, and it made two appointments in its branded drug business.

Chief Scientific Officer Susan Hall, who oversaw global research and development, will serve as a consultant on the Xiaflex cellulite treatment after her departure in March 2017, the Dublin-based company said in a Dec. 21 news release. Joseph Ciaffoni, the president of the branded pharmaceuticals unit in the U.S., will depart "in light of the significant organizational restructuring that has taken place," Endo said.

The drugmaker chose Patrick Barry as senior vice president of U.S. branded pharmaceuticals, effective immediately, Endo said. Barry will oversee all commercial activities for U.S. branded medicines, including strategy, new product planning, marketing and sales. Matthew Davis will become senior vice president of R&D for branded pharmaceuticals as of Jan. 3, 2017, the company said.

Barry most recently was general manager and head of North America general medicines for Sanofi. Davis most recently was the chief medical officer for Lupin Ltd. unit Lupin Pharmaceuticals Inc.